GlaxoSmithKline Pakistan Limited (PSX:GLAXO)

Market Cap	112.99B -5.6%
Revenue (ttm)	67.35B +10.1%
Net Income	10.51B +29.8%
EPS	33.00 +29.8%
Shares Out	318.47M
PE Ratio	10.75
Forward PE	9.90
Dividend	17.00 (4.79%)
Ex-Dividend Date	Apr 24, 2026

Volume	352,374
Open	344.25
Previous Close	n/a
Day's Range	342.00 - 357.00
52-Week Range	293.09 - 459.94
Beta	0.41
Analysts	Strong Buy
Price Target	516.67 (+45.63%)
Earnings Date	Aug 24, 2026

About GlaxoSmithKline Pakistan

GlaxoSmithKline Pakistan Limited, a biopharma company, engages in the discovery, development, and delivery of medicines and vaccines in Pakistan. It offers products in the anti-infective, dermatology, respiratory, immunology and inflammation, oncology, infectious diseases, HIV, and vaccines therapy areas. The company sells its products under the Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol, Shingrix, and Cutivate brands. It also exports its products. The company was founded in 2001 and is headquartered in Karachi, Pakista...

• Industry: Pharmaceuticals
• Sector: Healthcare
• Founded: 2001
• Employees: 1,606
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: GLAXO

Financial Performance

In 2025, GlaxoSmithKline Pakistan's revenue was 65.90 billion, an increase of 7.70% compared to the previous year's 61.19 billion. Earnings were 10.03 billion, an increase of 53.38%.